SCHEMBL6409778

SCHEMBL6409778

Cc1c(C(=O)O)[nH]c(C=C2C(=O)Nc3ccc(Br)cc32)c1CCC(=O)O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 12/20 0.75
KDR P35968 12/20 0.75
PDGFRB P09619 11/20 0.75
SRC P12931 2/20 0.65
AURKA O14965 5/20 0.63
EGFR P00533 4/20 0.55
RET P07949 3/20 0.55
FLT1 P17948 3/20 0.55
FLT3 P36888 2/20 0.55
MAP4K2 Q12851 2/20 0.55
STK3 Q13188 2/20 0.55
AURKB Q96GD4 2/20 0.55
ZAP70 P43403 2/20 0.55
GAK O14976 1/20 0.55
RPS6KA5 O75582 1/20 0.55
RPS6KA4 O75676 1/20 0.55
LATS1 O95835 1/20 0.55
CSNK2A2 P19784 1/20 0.55
MAP2K2 P36507 1/20 0.55
MAP2K1 Q02750 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6409774 1.00 FGFR1 (0.75) FGFR1KDRPDGFRBSRCAURKA
SCHEMBL6405619 0.90 FGFR1 (0.63) FGFR1KDRPDGFRBSRCAURKA
SCHEMBL6405621 0.90 FGFR1 (0.63) FGFR1KDRPDGFRBSRCAURKA
SCHEMBL6406975 0.90 FGFR1 (0.69) FGFR1KDRPDGFRBSRCAURKA
SCHEMBL6406978 0.90 FGFR1 (0.69) FGFR1KDRPDGFRBSRCAURKA
SCHEMBL6405826 0.88 ZAP70 (0.67) FGFR1KDRPDGFRBSRCAURKA
SCHEMBL6405823 0.88 ZAP70 (0.67) FGFR1KDRPDGFRBSRCAURKA
SCHEMBL6405120 0.87 KDR (0.65) FGFR1KDRPDGFRBSRCAURKA
SCHEMBL6405124 0.87 KDR (0.65) FGFR1KDRPDGFRBSRCAURKA
SCHEMBL4410717 0.86 KDR (1.00) FGFR1KDRPDGFRBSRCAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6855730-B2 3-methylidenyl-2-indolinone modulators of protein kinase SUGEN, INC. (US) 2005-02-15 US disclosed
US-20040067531-A1 Methods of modulating protein tyrosine kinase function with substituted indolinone compounds SUGEN, INC. 2004-04-08 US disclosed
US-20040024010-A1 3-methylidenyl-2-indolinone modulators of protein kinase SUGEN, INC. 2004-02-05 US disclosed
US-6531502-B1 Antitumor SUGEN, INC. 2003-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067531-A1 Methods of modulating protein tyrosine kinase function with substituted indolinone compounds ABL1, LCK, PNCK FGFR1 985/4885KDR 634/4885PDGFRB 622/4885
US-20040024010-A1 3-methylidenyl-2-indolinone modulators of protein kinase DMPK, MAP4K3, MAP3K20 FGFR1 2701/4885KDR 1617/4885PDGFRB 1860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.